On Wednesday, September 4, quotes on Athira Pharma, a small developer of therapies for neuronal health, plummeted 78% after the company reported that its Alzheimer’s treatment had not been found significantly more effective than placebo in a 26-week clinical trial. Despite this setback, Athira intends to continue working on the…